Miglitol prevents diet-induced obesity by stimulating brown adipose tissue and energy expenditure independent of preventing the digestion of carbohydrates

Endocrine Journal

Volumn 60, Issue 10, 2013, Pages 1117-1129

  Sasaki, Tsutomu ^a   Shimpuku, Mayumi ^a   Kitazumi, Tomoya ^a   Hiraga, Haruna ^a   Nakagawa, Yuko ^a   Shibata, Hiroshi ^a   Okamatsu Ogura, Yuko ^b   Kikuchi, Osamu ^a   Kim, Hye Jin ^a   Fujita, Yuki ^a   Maruyama, Jun ^a   Susanti, Vina Yanti ^a   Yokota Hashimoto, Hiromi ^a   Kobayashi, Masaki ^a   Saito, Masayuki ^c   Kitamura, Tadahiro ^a  

^a GUNMA UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c TENSHI COLLEGE   (Japan)

Author keywords

Adrenergic signaling; Alpha glucosidase inhibitor; Brown adipose tissue; Diet induced obesity; Energy expenditure

Indexed keywords

ACARBOSE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; GLUCAGON LIKE PEPTIDE 1; MIGLITOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; UNCOUPLING PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BROWN ADIPOSE TISSUE; CARBOHYDRATE ABSORPTION; CELL STRAIN 3T3; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; ENERGY EXPENDITURE; GENE EXPRESSION; HYPERGLYCEMIA; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; OBESITY; OXYGEN CONSUMPTION; PROADIPOCYTE; SIGNAL TRANSDUCTION;

1-DEOXYNOJIRIMYCIN; ACARBOSE; ADIPOCYTES, BROWN; ADIPOSE TISSUE, BROWN; ALPHA-GLUCOSIDASES; ANIMALS; ANTI-OBESITY AGENTS; CELL LINE; DIET, HIGH-FAT; DIETARY CARBOHYDRATES; DIGESTION; EATING; ENERGY METABOLISM; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED C57BL; OBESITY; OXYGEN CONSUMPTION; RECEPTORS, ADRENERGIC, BETA; SIGNAL TRANSDUCTION;

EID: 84886997169     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ13-0333     Document Type: Article

References (42)

1. Ginter E, Simko V (2012) Type 2 diabetes mellitus, pandemic in 21st century. Adv Exp Med Biol 771: 42-50.
2. Ginter E, Simko V (2012) Global prevalence and future of diabetes mellitus. Adv Exp Med Biol 771: 35-41.
3. Eckel RH, Kahn SE, Ferrannini E, Goldfine AB, Nathan DM, et al. (2011) Obesity and type 2 diabetes: what can be unified and what needs to be individualized? Diabetes Care 34: 1424-1430.
4. Meneghini LF, Orozco-Beltran D, Khunti K, Caputo S, Damci T, et al. (2011) Weight beneficial treatments for type 2 diabetes. J Clin Endocrinol Metab 96: 3337-3353.
5. Ledford H (2010) Slim spoils for obesity drugs. Nature 468: 878.
6. Colman E, Golden J, Roberts M, Egan A, Weaver J, et al. (2012) The FDA's assessment of two drugs for chronic weight management. N Engl J Med 367: 1577-1579.
7. van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, et al. (2005) Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 28: 154-163.
8. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, et al. (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359: 2072-2077.
9. Sels JP, Huijberts MS, Wolffenbuttel BH (1999) Miglitol, a new alpha-glucosidase inhibitor. Expert Opin Pharmacother 1: 149-156.
10. Shimabukuro M, Higa M, Yamakawa K, Masuzaki H, Sata M (2012) Miglitol, alpha-glycosidase inhibitor, reduces visceral fat accumulation and cardiovascular risk factors in subjects with the metabolic syndrome: A randomized comparable study. Int J Cardiol 2012 Jun 19. [Epub ahead of print].
11. Narita T, Yokoyama H, Yamashita R, Sato T, Hosoba M, et al. (2012) Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients. Diabetes Obes Metab 14: 283-287.
12. Lee A, Patrick P, Wishart J, Horowitz M, Morley JE (2002) The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab 4: 329-335.
13. Kim HJ, Kobayashi M, Sasaki T, Kikuchi O, Amano K, et al. (2012) Overexpression of FoxO1 in the hypothalamus and pancreas causes obesity and glucose intolerance. Endocrinology 153: 659-671.
14. Sasaki T, Kim HJ, Kobayashi M, Kitamura YI, Yokota-Hashimoto H, et al. (2010) Induction of hypothalamic Sirt1 leads to cessation of feeding via agouti-related peptide. Endocrinology 151: 2556-2566.
15. Irie Y, Asano A, Canas X, Nikami H, Aizawa S, et al. (1999) Immortal brown adipocytes from p53-knockout mice: differentiation and expression of uncoupling proteins. Biochem Biophys Res Commun 255: 221-225.
16. Nikolaev VO, Bunemann M, Hein L, Hannawacker A, Lohse MJ (2004) Novel single chain cAMP sensors for receptor-induced signal propagation. J Biol Chem 279: 37215-37218.
17. Kitamura T, Ogawa W, Sakaue H, Hino Y, Kuroda S, et al. (1998) Requirement for activation of the serine-threonine kinase Akt (protein kinase B) in insulin stimulation of protein synthesis but not of glucose transport. Mol Cell Biol 18: 3708-3717.
18. Masubuchi Y, Nakagawa Y, Ma J, Sasaki T, Kitamura T, et al. (2013) A novel regulatory function of sweet tastesensing receptor in adipogenic differentiation of 3T3-L1 cells. PLoS One 8: e54500.
19. Fernandez-Marcos PJ, Auwerx J (2011) Regulation of PGC-1alpha, a nodal regulator of mitochondrial biogenesis. Am J Clin Nutr 93: 884S-890.
20. Seale P, Kajimura S, Yang W, Chin S, Rohas LM, et al. (2007) Transcriptional control of brown fat determination by PRDM16. Cell Metab 6: 38-54.
21. Taylor SS, Yang J, Wu J, Haste NM, Radzio-Andzelm E, et al. (2004) PKA: a portrait of protein kinase dynamics. Biochim Biophys Acta 1697: 259-269.
22. Londos C, Honnor RC, Dhillon GS (1985) cAMP-dependent protein kinase and lipolysis in rat adipocytes. III. Multiple modes of insulin regulation of lipolysis and regulation of insulin responses by adenylate cyclase regulators. J Biol Chem 260: 15139-15145.
23. Egan JJ, Greenberg AS, Chang MK, Londos C (1990) Control of endogenous phosphorylation of the major cAMP-dependent protein kinase substrate in adipocytes by insulin and beta-adrenergic stimulation. J Biol Chem 265: 18769-18775.
24. Li X, Wang Y, Wang J, Fawcett JP, Zhao L, et al. (2007) Determination of miglitol in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 21: 247-251.
25. Nirogi RV, Kandikere VN, Shukla M, Mudigonda K, Maurya S, et al. (2006) Liquid chromatographic tandem mass spectrometry method for the quantification of miglitol in human plasma. Arzneimittelforschung 56: 328-336.
26. Ahr HJ, Boberg M, Brendel E, Krause HP, Steinke W (1997) Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man. Arzneimittelforschung 47: 734-745.
27. Minatoguchi S, Arai M, Uno Y, Kariya T, Nishida Y, et al. (1999) A novel anti-diabetic drug, miglitol, markedly reduces myocardial infarct size in rabbits. Br J Pharmacol 128: 1667-1672.
28. Beak SA, Small CJ, Ilovaiskaia I, Hurley JD, Ghatei MA, et al. (1996) Glucagon-like peptide-1 (GLP-1) releases thyrotropin (TSH): characterization of binding sites for GLP-1 on alpha-TSH cells. Endocrinology 137: 4130-4138.
29. Knauf C, Cani PD, Ait-Belgnaoui A, Benani A, Dray C, et al. (2008) Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure. Endocrinology 149: 4768-4777.
30. Young JB, Saville E, Rothwell NJ, Stock MJ, Landsberg L (1982) Effect of diet and cold exposure on norepinephrine turnover in brown adipose tissue of the rat. J Clin Invest 69: 1061-1071.
31. Trayhurn P, Ashwell M (1987) Control of white and brown adipose tissues by the autonomic nervous system. Proc Nutr Soc 46: 135-142.
32. Saito M, Okamatsu-Ogura Y, Matsushita M, Watanabe K, Yoneshiro T, et al. (2009) High incidence of metabolically active brown adipose tissue in healthy adult humans: effects of cold exposure and adiposity. Diabetes 58: 1526-1531.
33. Cypess AM, Lehman S, Williams G, Tal I, Rodman D, et al. (2009) Identification and importance of brown adipose tissue in adult humans. N Engl J Med 360: 1509-1517.
34. van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, Drossaerts JM, Kemerink GJ, et al. (2009) Cold-activated brown adipose tissue in healthy men. N Engl J Med 360: 1500-1508.
35. Virtanen KA, Lidell ME, Orava J, Heglind M, Westergren R, et al. (2009) Functional brown adipose tissue in healthy adults. N Engl J Med 360: 1518-1525.
36. Cypess AM, White AP, Vernochet C, Schulz TJ, Xue R, et al. (2013) Anatomical localization, gene expression profiling and functional characterization of adult human neck brown fat. Nat Med 19: 635-639.
37. Lidell ME, Betz MJ, Leinhard OD, Heglind M, Elander L, et al. (2013) Evidence for two types of brown adipose tissue in humans. Nat Med 19: 631-634.
38. Wu J, Bostrom P, Sparks LM, Ye L, Choi JH, et al. (2012) Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell 150: 366-376.
39. Desautels M, Dulos RA (1991) Effects of neonatal sympathectomy on brown fat development and susceptibility to high fat diet induced obesity in mice. Can J Physiol Pharmacol 69: 1868-1874.
40. Minokoshi Y, Saito M, Shimazu T (1986) Metabolic and morphological alterations of brown adipose tissue after sympathetic denervation in rats. J Auton Nerv Syst 15: 197-204.
41. Yoneshiro T, Aita S, Matsushita M, Okamatsu-Ogura Y, Kameya T, et al. (2011) Age-related decrease in cold-activated brown adipose tissue and accumulation of body fat in healthy humans. Obesity (Silver Spring) 19: 1755-1760.
42. Kawate R, Talan MI, Engel BT (1993) Aged C57BL/6J mice respond to cold with increased sympathetic nervous activity in interscapular brown adipose tissue. J Gerontol 48: B180-183.